{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T18:10:08Z","timestamp":1761156608697,"version":"3.37.3"},"reference-count":54,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,2,1]],"date-time":"2019-02-01T00:00:00Z","timestamp":1548979200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100010679","name":"Pasteur Institute of Iran","doi-asserted-by":"crossref","award":["921"],"award-info":[{"award-number":["921"]}],"id":[{"id":"10.13039\/501100010679","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Research Deputy at Golestan University of Medical Sciences","award":["35\/23551"],"award-info":[{"award-number":["35\/23551"]}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Virus Research"],"published-print":{"date-parts":[[2019,2]]},"DOI":"10.1016\/j.virusres.2018.12.014","type":"journal-article","created":{"date-parts":[[2018,12,29]],"date-time":"2018-12-29T16:33:39Z","timestamp":1546101219000},"page":"72-80","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"special_numbering":"C","title":["Non-replicating Newcastle Disease Virus as an adjuvant for DNA vaccine enhances antitumor efficacy through the induction of TRAIL and granzyme B expression"],"prefix":"10.1016","volume":"261","author":[{"given":"Alireza","family":"Mohebbi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mir Saeed","family":"Ebrahimzadeh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sanaz","family":"Baghban Rahimi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohsen","family":"Saeidi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alijan","family":"Tabarraei","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Seyed Reza","family":"Mohebbi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sadegh","family":"Shirian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ali","family":"Gorji","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amir","family":"Ghaemi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.virusres.2018.12.014_bib0005","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2016.1261240","article-title":"Oncolytic measles virus induces tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-mediated cytotoxicity by human myeloid and plasmacytoid dendritic cells","volume":"6","author":"Achard","year":"2017","journal-title":"Oncoimmunology"},{"issue":"1","key":"10.1016\/j.virusres.2018.12.014_bib0010","doi-asserted-by":"crossref","first-page":"36","DOI":"10.3390\/biomedicines2010036","article-title":"Oncolytic adenoviruses in cancer treatment","volume":"2","author":"Alemany","year":"2014","journal-title":"Biomedicines"},{"issue":"7","key":"10.1016\/j.virusres.2018.12.014_bib0015","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1007\/s12094-017-1613-6","article-title":"Rabies virus vaccine as an immune adjuvant against cancers and glioblastoma: new studies may resurrect a neglected potential","volume":"19","author":"Altinoz","year":"2017","journal-title":"Clin. Transl. Oncol."},{"issue":"1-2","key":"10.1016\/j.virusres.2018.12.014_bib0020","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.cellimm.2014.03.005","article-title":"Effects of inactivated parapoxvirus ovis on cellular and humoral events of the innate immune response in mice","volume":"289","author":"Anziliero","year":"2014","journal-title":"Cell. Immunol."},{"key":"10.1016\/j.virusres.2018.12.014_bib0025","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.jviromet.2014.05.013","article-title":"DNA vaccine encoding HPV-16 E7 with mutation in L-Y-C-Y-E pRb-binding motif induces potent anti-tumor responses in mice","volume":"206","author":"Bahrami","year":"2014","journal-title":"J. Virol. Methods"},{"issue":"3","key":"10.1016\/j.virusres.2018.12.014_bib0030","doi-asserted-by":"crossref","first-page":"21","DOI":"10.3390\/biomedicines4030021","article-title":"Capitalizing on Cancer Specific replication: oncolytic viruses as a versatile platform for the enhancement of Cancer immunotherapy strategies","volume":"4","author":"Bastin","year":"2016","journal-title":"Biomedicines"},{"key":"10.1016\/j.virusres.2018.12.014_bib0035","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1093\/oxfordjournals.jncimonographs.a003479","article-title":"Human papillomavirus and cervical cancer--burden and assessment of causality","volume":"31","author":"Bosch","year":"2003","journal-title":"J. Natl. Cancer Inst. Monographs"},{"issue":"10","key":"10.1016\/j.virusres.2018.12.014_bib0040","doi-asserted-by":"crossref","first-page":"1814","DOI":"10.1038\/mt.2009.154","article-title":"Vesicular stomatitis virus as a novel cancer vaccine vector to prime antitumor immunity amenable to rapid boosting with adenovirus","volume":"17","author":"Bridle","year":"2009","journal-title":"Mol.Ther."},{"issue":"1","key":"10.1016\/j.virusres.2018.12.014_bib0045","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1007\/BF00391826","article-title":"Estimation of liver tumor volume using different formulas - an experimental study in rats","volume":"105","author":"Carlsson","year":"1983","journal-title":"J. Cancer Res. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.virusres.2018.12.014_bib0050","doi-asserted-by":"crossref","first-page":"248","DOI":"10.4049\/jimmunol.176.1.248","article-title":"Virus or TLR agonists induce TRAIL-mediated cytotoxic activity of plasmacytoid dendritic cells","volume":"176","author":"Chaperot","year":"2006","journal-title":"J. Immunol. (Baltimore, Md.: 1950)"},{"key":"10.1016\/j.virusres.2018.12.014_bib0055","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.coi.2018.03.008","article-title":"Oncolytic viruses and immunity","volume":"51","author":"Chaurasiya","year":"2018","journal-title":"Curr. Opin. Immunol."},{"issue":"3","key":"10.1016\/j.virusres.2018.12.014_bib0060","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1111\/j.1365-2893.2007.00930.x","article-title":"Impaired TRAIL-dependent cytotoxicity of CD1c-positive dendritic cells in chronic hepatitis C virus infection","volume":"15","author":"Ciesek","year":"2008","journal-title":"J. Viral Hepat."},{"issue":"3","key":"10.1016\/j.virusres.2018.12.014_bib0065","doi-asserted-by":"crossref","first-page":"1356","DOI":"10.4049\/jimmunol.168.3.1356","article-title":"Increased susceptibility to tumor initiation and metastasis in TNF-related apoptosis-inducing ligand-deficient mice","volume":"168","author":"Cretney","year":"2002","journal-title":"J. Immunol. (Baltimore, Md.: 1950)"},{"issue":"2","key":"10.1016\/j.virusres.2018.12.014_bib0070","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1111\/j.1365-2567.2009.03058.x","article-title":"Following TRAIL\u2019s path in the immune system","volume":"127","author":"Falschlehner","year":"2009","journal-title":"Immunology"},{"issue":"1","key":"10.1016\/j.virusres.2018.12.014_bib0075","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12916-016-0623-5","article-title":"Cancer immunotherapy: the beginning of the end of cancer?","volume":"14","author":"Farkona","year":"2016","journal-title":"BMC Med."},{"issue":"1","key":"10.1016\/j.virusres.2018.12.014_bib0080","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1007\/s00262-007-0351-y","article-title":"Intratumoral injection of inactivated Sendai virus particles elicits strong antitumor activity by enhancing local CXCL10 expression and systemic NK cell activation","volume":"57","author":"Fujihara","year":"2008","journal-title":"Cancer Immunol. Immunother.: CII"},{"key":"10.1016\/j.virusres.2018.12.014_bib0085","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/s12929-016-0238-3","article-title":"Combination of the toll like receptor agonist and alpha-Galactosylceramide as an efficient adjuvant for cancer vaccine","volume":"23","author":"Gableh","year":"2016","journal-title":"J. Biomed. Sci."},{"issue":"2","key":"10.1016\/j.virusres.2018.12.014_bib0090","first-page":"119","article-title":"Genistein induces a protective immunomodulatory effect in a mouse model of cervical cancer","volume":"9","author":"Ghaemi","year":"2012","journal-title":"Iran. J. Immunol.: IJI"},{"issue":"3","key":"10.1016\/j.virusres.2018.12.014_bib0095","doi-asserted-by":"crossref","first-page":"525","DOI":"10.3892\/ijmm.2013.1244","article-title":"Newcastle disease virus Malaysian strain AF2240 induces apoptosis in MCF-7 human breast carcinoma cells at an early stage of the virus life cycle","volume":"31","author":"Ghrici","year":"2013","journal-title":"Int. J. Mol. Med."},{"issue":"6","key":"10.1016\/j.virusres.2018.12.014_bib0100","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1182\/blood-2009-07-235382","article-title":"Granzyme B produced by human plasmacytoid dendritic cells suppresses T-cell expansion","volume":"115","author":"Jahrsdorfer","year":"2010","journal-title":"Blood"},{"issue":"18","key":"10.1016\/j.virusres.2018.12.014_bib0105","doi-asserted-by":"crossref","first-page":"9624","DOI":"10.1128\/JVI.78.18.9624-9632.2004","article-title":"Intranasal immunization with inactivated influenza virus enhances immune responses to coadministered simian-human immunodeficiency virus-like particle antigens","volume":"78","author":"Kang","year":"2004","journal-title":"J. Virol."},{"issue":"9","key":"10.1016\/j.virusres.2018.12.014_bib0110","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1084\/jem.189.9.1451","article-title":"Type I interferons (IFNs) regulate tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) expression on human T cells: a novel mechanism for the antitumor effects of type I IFNs","volume":"189","author":"Kayagaki","year":"1999","journal-title":"J. Exp. Med."},{"issue":"4","key":"10.1016\/j.virusres.2018.12.014_bib0115","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/0166-0934(88)90132-2","article-title":"Titration of avirulent Newcastle disease virus by the plaque assay method","volume":"20","author":"Kournikakis","year":"1988","journal-title":"J. Virol. Methods"},{"issue":"1","key":"10.1016\/j.virusres.2018.12.014_bib0120","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1158\/0008-5472.CAN-06-1615","article-title":"Inactivated Sendai virus particles eradicate tumors by inducing immune responses through blocking regulatory T cells","volume":"67","author":"Kurooka","year":"2007","journal-title":"Cancer Res."},{"issue":"1-3","key":"10.1016\/j.virusres.2018.12.014_bib0125","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1007\/s12026-009-8141-6","article-title":"Therapeutic HPV DNA vaccines","volume":"47","author":"Lin","year":"2010","journal-title":"Immunol. Res."},{"issue":"23","key":"10.1016\/j.virusres.2018.12.014_bib0130","first-page":"6017","article-title":"Complete regression of human fibrosarcoma xenografts after local Newcastle disease virus therapy","volume":"54","author":"Lorence","year":"1994","journal-title":"Cancer Res."},{"issue":"12","key":"10.1016\/j.virusres.2018.12.014_bib0135","doi-asserted-by":"crossref","first-page":"6015","DOI":"10.1128\/JVI.01537-10","article-title":"Oncolytic specificity of Newcastle disease virus is mediated by selectivity for apoptosis-resistant cells","volume":"85","author":"Mansour","year":"2011","journal-title":"J. Virol."},{"issue":"2","key":"10.1016\/j.virusres.2018.12.014_bib0140","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1007\/s00705-016-3091-5","article-title":"Synergistic effect of programmed cell death protein 1 blockade and secondary lymphoid tissue chemokine in the induction of anti-tumor immunity by a therapeutic cancer vaccine","volume":"162","author":"Moeini","year":"2017","journal-title":"Arch. Virol."},{"issue":"3","key":"10.1016\/j.virusres.2018.12.014_bib0145","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1007\/s12250-013-3291-z","article-title":"Interleukin-12 as a genetic adjuvant enhances hepatitis C virus NS3 DNA vaccine immunogenicity","volume":"28","author":"Naderi","year":"2013","journal-title":"Virol. Sin."},{"issue":"42","key":"10.1016\/j.virusres.2018.12.014_bib0150","doi-asserted-by":"crossref","first-page":"6891","DOI":"10.1016\/j.vaccine.2010.08.011","article-title":"The hemagglutinin-neuraminidase gene of Newcastle Disease Virus: a powerful molecular adjuvant for DNA anti-tumor vaccination","volume":"28","author":"Ni","year":"2010","journal-title":"Vaccine"},{"issue":"10","key":"10.1016\/j.virusres.2018.12.014_bib0155","doi-asserted-by":"crossref","first-page":"1581","DOI":"10.1586\/14737140.8.10.1581","article-title":"Oncolytic viruses: a novel form of immunotherapy","volume":"8","author":"Prestwich","year":"2008","journal-title":"Expert Rev. Anticancer Ther."},{"issue":"4","key":"10.1016\/j.virusres.2018.12.014_bib0160","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1016\/j.ymthe.2018.01.019","article-title":"Pre-existing immunity to oncolytic virus potentiates its immunotherapeutic efficacy","volume":"26","author":"Ricca","year":"2018","journal-title":"Mol. Ther."},{"issue":"Pt 11","key":"10.1016\/j.virusres.2018.12.014_bib0165","doi-asserted-by":"crossref","first-page":"3121","DOI":"10.1099\/vir.0.19416-0","article-title":"Contribution of the length of the HN protein and the sequence of the F protein cleavage site to Newcastle disease virus pathogenicity","volume":"84","author":"Romer-Oberdorfer","year":"2003","journal-title":"J. Gen. Virol."},{"issue":"8","key":"10.1016\/j.virusres.2018.12.014_bib0170","doi-asserted-by":"crossref","first-page":"1951","DOI":"10.1007\/s00705-014-2024-4","article-title":"Comparing the effect of Toll-like receptor agonist adjuvants on the efficiency of a DNA vaccine","volume":"159","author":"Sajadian","year":"2014","journal-title":"Arch. Virol."},{"issue":"12","key":"10.1016\/j.virusres.2018.12.014_bib0175","doi-asserted-by":"crossref","first-page":"1757","DOI":"10.1517\/14712598.2015.1088000","article-title":"Oncolytic Newcastle disease virus as a prospective anti-cancer therapy. A biologic agent with potential to break therapy resistance","volume":"15","author":"Schirrmacher","year":"2015","journal-title":"Expert Opin. Biol. Ther."},{"issue":"6","key":"10.1016\/j.virusres.2018.12.014_bib0180","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1084\/jem.20070021","article-title":"Tumoricidal activity of TLR7\/8-activated inflammatory dendritic cells","volume":"204","author":"Stary","year":"2007","journal-title":"J. Exp. Med."},{"issue":"7","key":"10.1016\/j.virusres.2018.12.014_bib0185","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1007\/s00262-010-0821-5","article-title":"The anti-tumor effect of Newcastle disease virus HN protein is influenced by differential subcellular targeting","volume":"59","author":"Sui","year":"2010","journal-title":"Cancer Immunol. Immunother.: CII"},{"issue":"4","key":"10.1016\/j.virusres.2018.12.014_bib0190","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1097\/00045391-200307000-00008","article-title":"Newcastle disease virus-induced apoptosis in PC12 pheochromocytoma cells","volume":"10","author":"Szeberenyi","year":"2003","journal-title":"Am. J. Ther."},{"issue":"2","key":"10.1016\/j.virusres.2018.12.014_bib0195","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1038\/cdd.2014.134","article-title":"New insights into IL-12-mediated tumor suppression","volume":"22","author":"Tugues","year":"2015","journal-title":"Cell Death Differ."},{"issue":"25","key":"10.1016\/j.virusres.2018.12.014_bib0200","doi-asserted-by":"crossref","first-page":"21265","DOI":"10.1074\/jbc.M111.306480","article-title":"Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) induces death receptor 5 networks that are highly organized","volume":"287","author":"Valley","year":"2012","journal-title":"J. Biol. Chem."},{"issue":"9","key":"10.1016\/j.virusres.2018.12.014_bib0205","doi-asserted-by":"crossref","first-page":"e6982","DOI":"10.1371\/journal.pone.0006982","article-title":"Cyclophosphamide chemotherapy sensitizes tumor cells to TRAIL-dependent CD8 T cell-mediated immune attack resulting in suppression of tumor growth","volume":"4","author":"van der Most","year":"2009","journal-title":"PLoS One"},{"issue":"7","key":"10.1016\/j.virusres.2018.12.014_bib0210","doi-asserted-by":"crossref","DOI":"10.3390\/v9070186","article-title":"Targeting pattern recognition receptors (PRR) for vaccine adjuvantation: from synthetic PRR agonists to the potential of defective interfering particles of viruses","volume":"9","author":"Vasou","year":"2017","journal-title":"Viruses"},{"issue":"2","key":"10.1016\/j.virusres.2018.12.014_bib0215","first-page":"120","article-title":"Intradermal injection of Newcastle disease virus-modified autologous melanoma cell lysate and interleukin-2 for adjuvant treatment of melanoma patients with resectable stage III disease","volume":"1","author":"Voit","year":"2003","journal-title":"J. German Soc. Dermatol.: JDDG"},{"issue":"1","key":"10.1016\/j.virusres.2018.12.014_bib0220","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/0008-8749(90)90302-8","article-title":"Modification of tumor cells by a low dose of Newcastle disease virus. III. Potentiation of tumor-specific cytolytic T cell activity via induction of interferon-alpha\/beta","volume":"126","author":"von Hoegen","year":"1990","journal-title":"Cell. Immunol."},{"issue":"9376","key":"10.1016\/j.virusres.2018.12.014_bib0225","doi-asserted-by":"crossref","first-page":"2217","DOI":"10.1016\/S0140-6736(03)13778-6","article-title":"Cervical cancer","volume":"361","author":"Waggoner","year":"2003","journal-title":"Lancet"},{"issue":"5","key":"10.1016\/j.virusres.2018.12.014_bib0230","first-page":"502","article-title":"Two avirulent, lentogenic strains of Newcastle disease virus are cytotoxic for some human pancreatic tumor lines in vitro","volume":"13","author":"Walter","year":"2012","journal-title":"JOP: J. Pancreas"},{"issue":"11","key":"10.1016\/j.virusres.2018.12.014_bib0235","doi-asserted-by":"crossref","first-page":"1705","DOI":"10.1517\/14712598.7.11.1705","article-title":"Immunotherapy of cancer by IL-12-based cytokine combinations","volume":"7","author":"Weiss","year":"2007","journal-title":"Expert Opin. Biol. Ther."},{"issue":"1","key":"10.1016\/j.virusres.2018.12.014_bib0240","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1172\/JCI200110128","article-title":"IFN-gamma and Fas\/FasL are required for the antitumor and antiangiogenic effects of IL-12\/pulse IL-2 therapy","volume":"108","author":"Wigginton","year":"2001","journal-title":"J. Clin. Invest."},{"issue":"1","key":"10.1016\/j.virusres.2018.12.014_bib0245","doi-asserted-by":"crossref","first-page":"78","DOI":"10.3390\/v2010078","article-title":"Oncolytic viruses for Cancer therapy: overcoming the obstacles","volume":"2","author":"Wong","year":"2010","journal-title":"Viruses"},{"issue":"2","key":"10.1016\/j.virusres.2018.12.014_bib0250","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1038\/mt.2013.220","article-title":"Oncolytic virotherapy and immunogenic cancer cell death: sharpening the sword for improved cancer treatment strategies","volume":"22","author":"Workenhe","year":"2014","journal-title":"Mol. Ther."},{"issue":"2","key":"10.1016\/j.virusres.2018.12.014_bib0255","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1089\/cbr.2007.337","article-title":"In vitro induction of apoptosis in tumor cells by inactivated NDV and IAV","volume":"22","author":"Yang","year":"2007","journal-title":"Cancer Biother. Radiopharm."},{"issue":"11","key":"10.1016\/j.virusres.2018.12.014_bib0260","doi-asserted-by":"crossref","first-page":"3153","DOI":"10.4161\/21645515.2014.980686","article-title":"DNA vaccine for cancer immunotherapy","volume":"10","author":"Yang","year":"2014","journal-title":"Hum. Vaccin. Immunother."},{"issue":"4","key":"10.1016\/j.virusres.2018.12.014_bib0265","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1038\/mt.2008.286","article-title":"Enhancement of oncolytic properties of recombinant newcastle disease virus through antagonism of cellular innate immune responses","volume":"17","author":"Zamarin","year":"2009","journal-title":"Mol. Ther.: J. Am. Soc. Gene Ther."},{"issue":"8","key":"10.1016\/j.virusres.2018.12.014_bib0270","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1111\/j.1440-1681.2011.05662.x","article-title":"Newcastle disease virus: a promising agent for tumour immunotherapy","volume":"39","author":"Zhao","year":"2012","journal-title":"Clin. Exp. Pharmacol. Physiol."}],"container-title":["Virus Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S016817021830594X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S016817021830594X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,1,9]],"date-time":"2019-01-09T19:00:27Z","timestamp":1547060427000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S016817021830594X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,2]]},"references-count":54,"alternative-id":["S016817021830594X"],"URL":"https:\/\/doi.org\/10.1016\/j.virusres.2018.12.014","relation":{},"ISSN":["0168-1702"],"issn-type":[{"type":"print","value":"0168-1702"}],"subject":[],"published":{"date-parts":[[2019,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Non-replicating Newcastle Disease Virus as an adjuvant for DNA vaccine enhances antitumor efficacy through the induction of TRAIL and granzyme B expression","name":"articletitle","label":"Article Title"},{"value":"Virus Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.virusres.2018.12.014","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}